Apolipoprotein A1

Cleveland HeartLab A, Lipids, Test

NEW YORK DOH APPROVED: YES
CPT Code: 82172
Order Code: C122
ABN Requirement:  No
Synonyms: A-1 Apolipoprotein; Apo A-1
Specimen: Serum or EDTA Plasma
Volume: 0.5 mL
Minimum Volume: 0.2 mL
Container: Gel-barrier tube (SST, Tiger Top) or EDTA (Lavender Top) tube

Collection:

Serum:

  1. Collect and label sample according to standard protocols.
  2. Gently invert tube 5 times immediately after draw. DO NOT SHAKE.
  3. Allow blood to clot 30 minutes.
  4. Centrifuge at 1300 rcf for 10 minutes.

Plasma:

  1. Draw and gently invert 8 to 10 times.
  2. Place specimen on ice after draw.
  3. Centrifuge immediately for 10 minutes at 1300 RCF at room temperature.
  4. Pre-squeeze transfer pipet bulb and draw off approximately 2/3 of the upper plasma layer.
    Note: This ensures that the buffy coat and red cells remain undisturbed.
  5. Aliquot plasma into labeled transport tube and cap tightly. Discard original tube.
  6. Store transport tube refrigerated at 2-8°C until ready to ship.

Patient Preparation: Patient must be fasting 12 to 14 hours.

Transport: Store serum or EDTA plasma at 2°C to 8°C after collection and ship the same day per packaging instructions provided with the Cleveland HeartLab, Inc. shipping box.

Stability:

Ambient (15-25°C): 1 day
Refrigerated (2-8°C): 8 days
Frozen (-20°C): 2 months
Deep Frozen (-70°C): 2 months

Causes for Rejection: Specimens other than serum or EDTA plasma; improper labeling; samples not stored properly; samples older than stability limits

Methodology: Immunoturbidimetric

Turn Around Time: 1 to 3 days

Relative Risk:

Age/Gender Low Risk
mg/dL
Moderate Risk
mg/dL
High Risk
mg/dL
0-19 Years >120 115-120 <115
≥20 years, Female >130 na <131
≥20 years, Male >120 na <121

Use: Testing may be useful for individuals with hyperlipidemia or decreased levels of HDL-C. Apo A-1 testing may also be useful for individuals at risk of cardiovascular disease or with a family history of cardiovascular disease to better determine risk, and to monitor the efficacy of lifestyle and therapeutic interventions in individuals with established cardiovascular disease.

Limitations: In very rare cases gammopathy may cause unreliable results.